Brain training boosts daily life in schizophrenia
NCT ID NCT02879604
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a group-based cognitive training program for people with schizophrenia who have had the condition for less than 10 years. The program teaches practical strategies to work around memory, attention, and planning problems. Researchers compared the costs and daily functioning of those who took the training versus those who received usual care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
218 people
The number who actually took part.
- Started
-
Mar 2018
- Finished
-
Mar 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnostic with schizophrénie * Less than 10 years of the evolution of the disease Exclusion Criteria: * History of severe cranial trauma and / or neurological pathology with cognitive impairment * Ongoing participation in another study for treatment of negative or cognitive symptoms * Ongoing participation in a study on management in psychotherapy for cognitive disorders and negative symptoms
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alpes Isère Hospital
Saint-Égrève, 38521, France
-
Charles Perrens Hospital
Bordeaux, 33076, France
-
Chenevier Hospital
Créteil, 94000, France
-
Gabriel-Montpied Univesity Hospital
Clermont-Ferrand, 63003, France
-
La Conception Hospital
Marseille, 13005, France
-
Le Vinatier Hospital
Bron, 69678, France
-
Louis Mourier Hospital
Colombes, 92701, France
-
Montpellier University Hospital
Montpellier, 34295, France
-
Strasbourg University Hospital
Strasbourg, 67091, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Automatic measurement of antipsychotic medication adherence in schizophrenia through speech (OBSERVSPEECH)
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug